BioCentury | Mar 31, 2021
Regulation

March 31 Quick Takes: Basket of EU approvals includes MS, SMA drugs; plus Amarin, AbbVie, Cara-Vifor

...for AbbVie’s atogepantAbbVie Inc. (NYSE:ABBV) said FDA has accepted an NDA for atogepant, an oral CGRP...
...Inc. Vifor Pharma Ltd. AbbVie Inc. Novartis AG F. Hoffmann-La Roche Ltd. Amarin Corp. plc Survival of motor neuron 2 centromeric (SMN2) Calcitonin gene-related peptide (CGRP) Kappa...
BioCentury | Jan 20, 2021
Product Development

Alzheimer’s marks fourth late-stage miss for Biohaven’s glutamate modulator

...non-significant findings; top-line data from that trial are expected this year. While troriluzole has struggled, Biohaven’s CGRP...
...Phase III to expand the therapy into the prevention setting. It’s also developing a follow-on CGRP...
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

...to support a submission. Minerva slipped $1 (26%) to $2.89 on Tuesday.Biohaven, Sosei Heptares in CGRP...
...to a portfolio of small molecule CGRP receptor antagonists, including preclinical therapy HTL0022562, to treat CGRP-mediated...
...funding, and is eligible for $370 million in milestones, plus royalties. Biohaven markets one oral CGRP...
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

...programs against validated chronic disease targets, including CGRP...
...difficult and have newer biology,” Hu said. “With CGRP...
...leapfrogging to front of line,” Hu said.Vaxxinity’s CGRP...
BioCentury | Oct 16, 2020
Deals

With Disarm deal, Atlas returns to Lilly to take neuro program forward

...in CNS and nervous system diseases in general.” Rhodes said Lilly’s 2014 deal to reacquire its anti-CGRP...
...direct and positive experience with them,” said Rhodes. FDA approved Emgality for migraine prevention in 2018. TARGETSCGRPcalcitonin gene-related peptide SARM1...
BioCentury | Oct 3, 2020
Product Development

Oral drugs and treatments for life-threatening diseases stand out among new product launches

...Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN). Sales of the drug, which was the first oral CGRP...
...it to market, jumped 708% from $1.2 million to $9.7 million. Nurtec beat competing injectable CGRP...
...a virtual launch and prioritized virtual channels to engage with patients, physicians and pharmacies. Another oral CGRP...
BioCentury | Sep 11, 2020
Product Development

Sept. 10 Quick Takes: approvals for Zai, GSK and Phase III readouts for Satsuma, Amryt and Takeda; plus Houston Methodist, MassBio and JPM

...had aimed to address acute migraine even in patients who achieved fewer migraine days with CGRP...
...virtual in 2021The 2021 J.P. Morgan Healthcare Conference will be held virtually Jan. 11-14. TARGETSCGRPCalcitonin gene-related peptide BC...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...headed for FDA The Phase III ADVANCE trial of atogepant, an orally administered small molecule CGRP...
...drug, a 31% year-over-year increase (see “Merck Looks to Lower Barriers” ). Targets CGRP - Calcitonin gene-related peptide...
...Drug Administration (FDA) Truvian Sciences Inc. Shanghai Henlius Biotech Inc. Alector Inc. Accord Healthcare Ltd. Ascletis Pharma Inc. Merck & Co. Inc. Calcitonin gene-related peptide (CGRP) receptor Programmed...
BioCentury | Jul 10, 2020
Finance

How buysiders are sizing up commercial launches during the pandemic

...the market without a hitch in 1H20. And some saw an unanticipated boost. The oral CGRP...
...partner at PJT Partners. Biohaven’s migraine drug is a good example. As the only oral CGRP...
...worked.” Targets BCMA (TNFRSF17; CD269) - Tumor necrosis factor receptor superfamily member 17 CGRP - Calcitonin gene-related peptide...
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

...infection in patients who need supplemental oxygen. The double-blind study of the intranasal small molecule CGRP...
...antagonist will begin within weeks. Biohaven said that acute lung injury induces the release of CGRP...
...Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Targets CGRP - Calcitonin gene-related peptide...
Items per page:
1 - 10 of 241